Your account is not claimed yet. You can sign up with ORCID to claim your account.

Molly Ann Taylor (Molly A Taylor)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Topics

Magnetic Resonance

Cross Sectional

Top Venues

Molecular cancer therapeutics

International journal of molecular sciences

Journal for immunotherapy of cancer

Case Western Reserve University School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Case Western Reserve University School of Medicine

United States

PHD :: Pharmacology

Publications

Claire Emily Fletcher, Molly Ann Taylor, Charlotte Lynne Bevan
PLK1 Regulates MicroRNA Biogenesis through Drosha Phosphorylation. International journal of molecular sciences 24 (18) (2023)
Larissa S Carnevalli, Molly Ann Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes, Sigourney Bell, Theresa A Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E Critchlow, Teresa Klinowska, Stephen E Fawell, Simon T Barry
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition. Molecular cancer therapeutics 20 (6) (2021)
Molly Ann Taylor, Adina M Hughes, Josephine Walton, Anna M L Coenen-Stass, Lukasz Magiera, Lorraine Mooney, Sigourney Bell, Anna D Staniszewska, Linda C Sandin, Simon T Barry, Amanda Watkins, Larissa S Carnevalli, Elizabeth L Hardaker
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. Journal for immunotherapy of cancer 7 (1) (2019)
Sophie Langdon, Adina M Hughes, Molly Ann Taylor, Elizabeth A Kuczynski, Deanna A Mele, Oona Delpuech, Laura Jarvis, Anna Staniszewska, Sabina Cosulich, Larissa S Carnevalli, Charles Sinclair
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology 7 (8) (2018)